Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

Abstract Background This study was designed to investigate the clinical application, efficacy, and safety of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer in the real world. Methods A retrospective, observational analysis was conducted on patients treated with ICIs in four tert...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Meiling Sun, Huaijun Ji, Ning Xu, Peng Jiang, Tao Qu, Yu Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2022-07-01
Edice:	BMC Cancer
Témata:	Immune checkpoint inhibitors (ICIs) PD-L1 inhibitor NSCLC Objective response rate Disease control rate Median progression-free survival
On-line přístup:	https://doi.org/10.1186/s12885-022-09843-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!